Health Economics›Esophageal adenocarcinoma›Metastatic or locally advanced disease subsequent lines of therapy

Metastatic or locally advanced disease subsequent lines of therapy

Esophageal adenocarcinoma · 12 regimens

Cost estimates only — modelled on a typical patient (BSA 1.7 m², 70 kg, CrCl 90 mL/min) using the cheapest available formulary presentation. Excludes vial wastage, facility fees, supportive care, and infusion consumables. Not for billing, formulary decisions, or clinical use.

Filters

Y-axis

Cost vs Efficacy · 1 point

Fully pricedPartial pricing

Regimen	Biomarker	Cost/cycle ↓	Cycle	PFS ↕	OS ↕	Est. cycles	Course cost ↕	Evidence
Paclitaxel and Ramucirumab Variant #01	—	R 98 182	28d	—	9.6 mo	2	R 196 364 PFS proxy	1
Ramucirumab monotherapy Variant #01	—	R 48 173	14d	—	5.2 mo	2	R 96 346 PFS proxy	1
Cetuximab monotherapy Variant #07	—	R 11 811	180d	—	~8.1 mo	~2	~R 23 621 PFS proxy · indirect	3
Docetaxel monotherapy Variant #02	—	R 2 921	28d	—	5.2 mo	2	R 5 843 PFS proxy	1
Irinotecan monotherapy Variant #01	—	R 2 716	42d	~2.3 mo	~8.5 mo	~11	~R 29 874 PFS proxy · indirect	16
Irinotecan and Mitomycin Variant #01	—	R 2 040	28d	—	—	~7	~R 14 280 indirect	—
Paclitaxel monotherapy Variant #02	—	R 734	28d	—	7.4 mo	6	R 4 406 PFS proxy	1
Placebo Partial	—	—	—	—	4.7 mo	—	—	1
Nivolumab monotherapy Variant #01 Partial	—	—	14d	—	5.3 mo	2	—	1
Best supportive care Partial	—	—	—	~1.7 mo	~4.3 mo	—	—	14
Irinotecan liposomal monotherapy Variant #01 Partial	—	—	21d	—	—	~2	—	—
Apatinib monotherapy Variant #01 Partial	—	—	28d	—	6.5 mo	2	—	1

12 of 12 regimens shown